Risk factors for critical ITP bleeds in patients with ITP presenting to the ER with platelet counts less than 20 × 109/L (adults, n = 296; children, n = 930)
| Variables . | Adults . | Children . | ||
|---|---|---|---|---|
| Total patients with ITP . | Critical bleeding, n (%) . | Total patients with ITP . | Critical bleeding, n (%) . | |
| Overall | 296 | 15 (5.1) | 930 | 13 (1.4) |
| Age, y | ||||
| ≥65 | 104 | 9 (8.7) | — | — |
| <65 | 191 | 6 (3.1) | — | — |
| Age, y | ||||
| ≥12 | — | — | 200 | 6 (3.0) |
| <12 | — | — | 725 | 7 (1.0) |
| Sex | ||||
| Female | 173 | 7 (4.0) | 417 | 9 (2.2) |
| Male | 122 | 7 (5.7) | 508 | 4 (0.8) |
| ITP disease stage | ||||
| Newly diagnosed ITP (<3 months) | 171 | 8 (4.7) | 744 | 6 (0.8) |
| Persistent ITP (3-12 months) | 15 | 1 (6.7) | 53 | 3 (5.7) |
| Chronic ITP (>12 months) | 74 | 5 (6.8) | 92 | 3 (3.3) |
| Myocardial infarction | ||||
| Yes | 13 | 2 (15.4) | — | — |
| No | 283 | 13 (4.6) | — | — |
| CHF | ||||
| Yes | 18 | 5 (27.8) | — | — |
| No | 278 | 10 (3.6) | — | — |
| CVA or TIA | ||||
| Yes | 18 | 5 (27.8) | — | — |
| No | 278 | 10 (3.6) | — | — |
| COPD | ||||
| Yes | 14 | 2 (14.3) | — | — |
| No | 282 | 13 (4.6) | — | — |
| Rituximab in last 6 months | ||||
| Yes | 8 | 0 (0.0) | 5 | 2 (40.0) |
| No | 284 | 15 (5.3) | 921 | 11 (1.2) |
| ITP treatment at presentation | ||||
| Yes | 89 | 4 (4.5) | 98 | 6 (6.1) |
| No | 206 | 11 (5.3) | 828 | 7 (0.8) |
| Antiplatelets at presentation | ||||
| Yes | 40 | 1 (2.5) | 6 | 0 (0.0) |
| No | 252 | 14 (5.6) | 921 | 13 (1.4) |
| Anticoagulants at presentation | ||||
| Yes | 16 | 3 (18.6) | 1 | 0 (0.0) |
| No | 277 | 12 (4.3) | 917 | 13 (1.4) |
| Variables . | Adults . | Children . | ||
|---|---|---|---|---|
| Total patients with ITP . | Critical bleeding, n (%) . | Total patients with ITP . | Critical bleeding, n (%) . | |
| Overall | 296 | 15 (5.1) | 930 | 13 (1.4) |
| Age, y | ||||
| ≥65 | 104 | 9 (8.7) | — | — |
| <65 | 191 | 6 (3.1) | — | — |
| Age, y | ||||
| ≥12 | — | — | 200 | 6 (3.0) |
| <12 | — | — | 725 | 7 (1.0) |
| Sex | ||||
| Female | 173 | 7 (4.0) | 417 | 9 (2.2) |
| Male | 122 | 7 (5.7) | 508 | 4 (0.8) |
| ITP disease stage | ||||
| Newly diagnosed ITP (<3 months) | 171 | 8 (4.7) | 744 | 6 (0.8) |
| Persistent ITP (3-12 months) | 15 | 1 (6.7) | 53 | 3 (5.7) |
| Chronic ITP (>12 months) | 74 | 5 (6.8) | 92 | 3 (3.3) |
| Myocardial infarction | ||||
| Yes | 13 | 2 (15.4) | — | — |
| No | 283 | 13 (4.6) | — | — |
| CHF | ||||
| Yes | 18 | 5 (27.8) | — | — |
| No | 278 | 10 (3.6) | — | — |
| CVA or TIA | ||||
| Yes | 18 | 5 (27.8) | — | — |
| No | 278 | 10 (3.6) | — | — |
| COPD | ||||
| Yes | 14 | 2 (14.3) | — | — |
| No | 282 | 13 (4.6) | — | — |
| Rituximab in last 6 months | ||||
| Yes | 8 | 0 (0.0) | 5 | 2 (40.0) |
| No | 284 | 15 (5.3) | 921 | 11 (1.2) |
| ITP treatment at presentation | ||||
| Yes | 89 | 4 (4.5) | 98 | 6 (6.1) |
| No | 206 | 11 (5.3) | 828 | 7 (0.8) |
| Antiplatelets at presentation | ||||
| Yes | 40 | 1 (2.5) | 6 | 0 (0.0) |
| No | 252 | 14 (5.6) | 921 | 13 (1.4) |
| Anticoagulants at presentation | ||||
| Yes | 16 | 3 (18.6) | 1 | 0 (0.0) |
| No | 277 | 12 (4.3) | 917 | 13 (1.4) |
COPD, chronic obstructive pulmonary disease.